Phase II Neoadjuvant Trial of Nivolumab in Combination With HF10 Oncolytic Viral Therapy in Resectable Stage IIIB, IIIC, IVM1a Melanoma (Neo-NivoHF10)

Trial Profile

Phase II Neoadjuvant Trial of Nivolumab in Combination With HF10 Oncolytic Viral Therapy in Resectable Stage IIIB, IIIC, IVM1a Melanoma (Neo-NivoHF10)

Recruiting
Phase of Trial: Phase II

Latest Information Update: 29 Dec 2017

At a glance

  • Drugs Canerpaturev (Primary) ; Nivolumab (Primary)
  • Indications Malignant melanoma
  • Focus Therapeutic Use
  • Acronyms Neo-NivoHF10
  • Most Recent Events

    • 21 Dec 2017 According to a Takara Bio media release, has entered into an agreement with Huntsman Cancer Institute (HCI) to supply HF10 as an investigational drug. Under the agreement HCI will conduct this trial.
    • 13 Dec 2017 Status changed from not yet recruiting to recruiting.
    • 13 Nov 2017 Planned initiation date changed from 1 Oct 2017 to 1 Jan 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top